Blog Archive
-
▼
2008
(233)
-
▼
February
(16)
- DiaMedica, DM-99 Shown to Improve Glucose Metaboli...
- Bentley Pharmaceuticals, Phase II India clinical s...
- Zealand Pharma, Phase III program for AVE0010/ZP10
- ConjuChem, Phase II Study of PC-DACTM:Exendin-4
- InteKrin Therapeutics' INT131, Phase IIb study in ...
- Lilly , KwikPen for Humalog and Humalog Mixtures
- Kinetic Concepts, V.A.C.Therapy to be More Efficac...
- t+ Medical, Alliance with Lifescan, Inc. to improv...
- Lipomics Technologies, Insulin Resistance Research...
- Biovail , Canadian Commercial Availability of 1,00...
- Geron, Second U.S. Patent for Production of Pancre...
- DiaKine Therapeutics’ Anti-Inflammatory Drugs
- Healthcare Providers Direct, First Accurate and Ef...
- Novagali Pharma, FDA Clearance of IND for US Clini...
- Immunosyn, First Phase “Proof of Concept Trial” in...
- Genaera, Diabetes IND In Effect for Trodusquemine ...
-
▼
February
(16)
Monday, February 25, 2008
Lilly , KwikPen for Humalog and Humalog Mixtures
Feb 21, 2008 - Completing an unprecedented year of innovation in insulin delivery devices, Eli Lilly and Company (LLY) announced the launch of KwikPen™, a new insulin pen prefilled with the Humalog® (insulin lispro injection [rDNA origin]) brand of insulins. KwikPen is the third new insulin pen Lilly has launched in the last 12 months to help improve the daily management of diabetes, following the successful launches in 2007 of HumaPen® MEMOIR™ -- the world's first digital insulin pen with memory -- and HumaPen® LUXURA™ HD, a reusable pen for people who need insulin dosing in smaller increments... Lilly's Press Release-